Malignant News and Research

RSS

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Researchers at the University of California Los Angeles (UCLA) have found that a second molecular pathway may need to be blocked to prevent malignant cells from creating new blood vessels [angiogenesis]. A study of patients with pancreatic cancer showed that CXCL5 may be a key molecule in the angiogenesis switch—the point at which cells stop being normal and start producing blood vessels that feed malignancy.

14 Oct 2009

Researchers discover new cancer gene that causes adenoid cystic carcinoma

The cancer caused by this new cancer gene is called adenoid cystic carcinoma and is a slow-growing but deadly form of cancer. The research group can now show that the gene is found in 100% of these tumours, which means that a genetic test can easily be used to make a correct diagnosis.

14 Oct 2009

New diagnostic technology to detect breast cancer

"We were ready to start a family when a mammogram revealed an abnormal mass in my left breast," said Staci Sansolo, 34, of New Jersey. A biopsy revealed the mass was not cancer, but a second-round test found another area of concern.

14 Oct 2009

Decreased expression of tumor suppressor gene PTEN transforms neurofibromas into cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.

14 Oct 2009

Researchers identify genes that play a role in the development of endometrial cancer

Researchers at the University of Gothenburg, Sweden, have identified two genes believed to play a role in the development of endometrial cancer. These results may eventually lead to better diagnosis and treatment of this increasingly common form of cancer.

12 Oct 2009

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor. The findings suggest a new standard protocol could improve survival nearly two-fold for pediatric patients with choroid plexus tumors, as reported at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP).

12 Oct 2009

Skin cancer patients may benefit from smaller surgical margins

Many skin cancer patients fare just as well when surgeons remove about one inch of normal-looking tissue around the lesion instead of a larger safety margin, according to a new systematic review.

7 Oct 2009

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.

6 Oct 2009

pDCs promote growth and survival of malignant myeloma cells

Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor - to switch from defending the body against disease to shielding the myeloma cells from harm - Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Research study reveals primary chemotherapy benefits

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.

3 Oct 2009

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting. This novel approach to the diagnosis of lung cancer demonstrated a high level of sensitivity (97%) and accuracy (82%).

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

TMS closes final tranche of Series E Preferred Financing to a total of $6 million

TechniScan Medical Systems (TMS) Inc., a Salt Lake City-based developer of ultrasound technology for breast imaging, announced the close of the final tranche of their Series E Preferred Financing of $1.1 million, bringing the total raised in the Series E financing to just over $6 million.

1 Oct 2009

Scientists report new development for diagnosing malignant melanoma

Scientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer. Their study is scheduled for the September 10 issue of the ACS' Journal of the Medicinal Chemistry, a bi-weekly publication.

1 Oct 2009

Coupling electrosurgery with mass spectrometry for real-time identification of tumor tissues

Instead of the classic scalpel, surgeons can also operate with an electroscalpel. A significant advantage to this technique is that while a cut is being made, blood vessels are closed off and hemorrhaging eliminated. Now another advantage may be added as well: a German-Hungarian research team has developed a mass-spectrometry-based technique by which tissues can be analyzed during a surgical procedure.

30 Sep 2009

Researchers find new ways to treat Myelodysplastic Syndrome

Van Andel Research Institute (VARI) researchers are one step closer to finding new ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia.

30 Sep 2009

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

BSD Medical Corporation announced today that the University of California, San Francisco Medical Center (UCSF) has acquired a BSD-500 Hyperthermia System (BSD-500). UCSF is a world leader in hyperthermia and has the largest and most versatile hyperthermia program on the West Coast, and its world-renowned Radiation Oncology team has added the capabilities of the BSD-500 to its growing hyperthermia cancer treatment program.

29 Sep 2009

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 1/2 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090 in hematologic malignancies with a once-a-week dosing schedule.

29 Sep 2009

Malignant News and Research

Blocking newly discovered second molecular pathway may prevent angiogenesis: UCLA researchers

Researchers discover new cancer gene that causes adenoid cystic carcinoma

New diagnostic technology to detect breast cancer

Decreased expression of tumor suppressor gene PTEN transforms neurofibromas into cancer

Researchers identify genes that play a role in the development of endometrial cancer

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

Skin cancer patients may benefit from smaller surgical margins

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

pDCs promote growth and survival of malignant myeloma cells

Schering-Plough receives FDA recommendation approval for PEGINTRON

Research study reveals primary chemotherapy benefits

New molecular imaging technique raises hope for common malignant female tumor

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

TMS closes final tranche of Series E Preferred Financing to a total of $6 million

Scientists report new development for diagnosing malignant melanoma

Coupling electrosurgery with mass spectrometry for real-time identification of tumor tissues

Researchers find new ways to treat Myelodysplastic Syndrome

San Francisco Medical Center acquires a BSD-500 Hyperthermia System

Synta commences Phase 1/2 clinical study of novel Hsp90 inhibitor in hematologic malignancies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News